» Articles » PMID: 38165377

Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS

Abstract

Background And Objectives: Progression independent of relapse activity (PIRA) is a crucial determinant of overall disability accumulation in multiple sclerosis (MS). Accelerated brain atrophy has been shown in patients experiencing PIRA. In this study, we assessed the relation between PIRA and neurodegenerative processes reflected by (1) longitudinal spinal cord atrophy and (2) brain paramagnetic rim lesions (PRLs). Besides, the same relationship was investigated in progressive MS (PMS). Last, we explored the value of cross-sectional brain and spinal cord volumetric measurements in predicting PIRA.

Methods: From an ongoing multicentric cohort study, we selected patients with MS with (1) availability of a susceptibility-based MRI scan and (2) regular clinical and conventional MRI follow-up in the 4 years before the susceptibility-based MRI. Comparisons in spinal cord atrophy rates (explored with linear mixed-effect models) and PRL count (explored with negative binomial regression models) were performed between: (1) relapsing-remitting (RRMS) and PMS phenotypes and (2) patients experiencing PIRA and patients without confirmed disability accumulation (CDA) during follow-up (both considering the entire cohort and the subgroup of patients with RRMS). Associations between baseline MRI volumetric measurements and time to PIRA were explored with multivariable Cox regression analyses.

Results: In total, 445 patients with MS (64.9% female; mean [SD] age at baseline 45.0 [11.4] years; 11.2% with PMS) were enrolled. Compared with patients with RRMS, those with PMS had accelerated cervical cord atrophy (mean difference in annual percentage volume change [MD-APC] -1.41; = 0.004) and higher PRL load (incidence rate ratio [IRR] 1.93; = 0.005). Increased spinal cord atrophy (MD-APC -1.39; = 0.0008) and PRL burden (IRR 1.95; = 0.0008) were measured in patients with PIRA compared with patients without CDA; such differences were also confirmed when restricting the analysis to patients with RRMS. Baseline volumetric measurements of the cervical cord, whole brain, and cerebral cortex significantly predicted time to PIRA (all ≤ 0.002).

Discussion: Our results show that PIRA is associated with both increased spinal cord atrophy and PRL burden, and this association is evident also in patients with RRMS. These findings further point to the need to develop targeted treatment strategies for PIRA to prevent irreversible neuroaxonal loss and optimize long-term outcomes of patients with MS.

Citing Articles

Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.

Azzimonti M, Preziosa P, Pagani E, Meani A, Margoni M, Rubin M J Neurol. 2025; 272(3):228.

PMID: 39998642 DOI: 10.1007/s00415-025-12979-4.


A Window into New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current Perspective.

Guerra T, Iaffaldano P Int J Mol Sci. 2025; 26(3).

PMID: 39940654 PMC: 11817336. DOI: 10.3390/ijms26030884.


Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance.

Dal-Bianco A, Oh J, Sati P, Absinta M Ther Adv Neurol Disord. 2024; 17():17562864241306684.

PMID: 39711984 PMC: 11660293. DOI: 10.1177/17562864241306684.


Should We Consider Neurodegeneration by Itself or in a Triangulation with Neuroinflammation and Demyelination? The Example of Multiple Sclerosis and Beyond.

Perdaens O, van Pesch V Int J Mol Sci. 2024; 25(23.

PMID: 39684351 PMC: 11641818. DOI: 10.3390/ijms252312637.


Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.

Gaitan M, Marquez R, Ayerbe J, Reich D Mult Scler. 2024; 30(5_suppl):48-60.

PMID: 39658905 PMC: 11637223. DOI: 10.1177/13524585241301303.


References
1.
Portaccio E, Bellinvia A, Fonderico M, Pasto L, Razzolini L, Totaro R . Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain. 2022; 145(8):2796-2805. DOI: 10.1093/brain/awac111. View

2.
Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea R, Rahmanzadeh R . Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurol. 2022; 79(7):682-692. PMC: 9112138. DOI: 10.1001/jamaneurol.2022.1025. View

3.
Trapp B, Peterson J, Ransohoff R, Rudick R, Mork S, Bo L . Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998; 338(5):278-85. DOI: 10.1056/NEJM199801293380502. View

4.
Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017; 17(2):162-173. DOI: 10.1016/S1474-4422(17)30470-2. View

5.
Fartaria M, Kober T, Granziera C, Cuadra M . Longitudinal analysis of white matter and cortical lesions in multiple sclerosis. Neuroimage Clin. 2019; 23:101938. PMC: 6658829. DOI: 10.1016/j.nicl.2019.101938. View